Literature DB >> 28306564

Psychopharmacological treatment of schizophrenia during pregnancy and lactation.

Alexandra B Whitworth.   

Abstract

PURPOSE OF REVIEW: It is necessary, in every-day clinical life when treating pregnant women with mental diseases, to reach quick decisions derived from recent comprehensive information. The knowledge of the use of antipsychotics in pregnancy has increased considerably in the last years. This review tries to summarize important considerations and facilitate clinical decisions. RECENT
FINDINGS: This review will cover not only the effects of exposure during pregnancy on outcomes, postnatal adaption syndrome and lactation, but also pharmacokinetic considerations on the use of antipsychotics during pregnancy.
SUMMARY: The recent publications have found only minimally increased risks for certain malformations, after using ever more sophisticated statistical models of analysis and reassuring amounts of data. Taken together, the quality of the studies has greatly improved and the results are reassuring with respect to the safety of the use of antipsychotics during pregnancy. The rates of weight gain and gestational diabetes warrant closer attention in the clinical setting.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28306564     DOI: 10.1097/YCO.0000000000000329

Source DB:  PubMed          Journal:  Curr Opin Psychiatry        ISSN: 0951-7367            Impact factor:   4.741


  3 in total

1.  Antipsychotic Exposure in Pregnancy and the Risk of Gestational Diabetes: A Systematic Review and Meta-analysis.

Authors:  Suat Kucukgoncu; Sinan Guloksuz; Kubra Celik; Mert Ozan Bahtiyar; Jurjen J Luykx; Bart P F Rutten; Cenk Tek
Journal:  Schizophr Bull       Date:  2020-02-26       Impact factor: 9.306

Review 2.  Women who suffer from schizophrenia: Critical issues.

Authors:  Mary V Seeman
Journal:  World J Psychiatry       Date:  2018-11-09

Review 3.  [Antipsychotics during pregnancy: a systematic review].

Authors:  Thomas Hillemacher; Susanne Simen; Marie-Kathrin Rehme; Helge Frieling
Journal:  Nervenarzt       Date:  2020-09-30       Impact factor: 1.214

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.